Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The provided evaluation text’s central medical claim (serious skin rashes requiring hospitalization and discontinuation, including Stevens-Johnson syndrome and toxic epidermal necrolysis) is directly supported by the supplied FDA label sections (Boxed Warning 5.1 and Warnings & Precautions 5.1).
Category Scores
Accurate Statements
SUBVENITE can cause serious skin rashes requiring hospitalization and discontinuation of treatment (including Stevens-Johnson syndrome and toxic epidermal necrolysis).
Supported by Boxed Warning 5.1 and Warnings & Precautions (5.1), which state serious rashes may require hospitalization and discontinuation and list Stevens-Johnson syndrome and toxic epidermal necrolysis among rashes leading to hospitalization.
Unsupported Statements
Contradictions
Important Omissions
No specific incidence rates, timing (e.g., mostly within 2–8 weeks), risk factors (e.g., valproate, HLA-B*1502), or patient counseling details are included in the evaluated claim.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated statement aligns with the label’s boxed warning content regarding serious skin rash risk and appropriate severity descriptors; it does not add or omit safety-relevant qualifiers that would materially mislead within the scope of the claim.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
None for the central claim; minor omission of additional boxed-warning details (rates, timing, risk factors) relative to the full label context.
Suggested Improvement
When summarizing the boxed warning, optionally include key label qualifiers such as timing (mostly 2–8 weeks), key risk factors (e.g., valproate, dose escalation, HLA-B*1502), and the instruction to discontinue at first sign of rash (unless clearly not drug-related).